CTLA4-Ig Abatacept Ameliorates Proteinuria by Regulating Circulating Treg/IL-17 in Adriamycin-Induced Nephropathy Rats

• Published in: BioMed research international 2020, Vol.2020 (2020), p.1-9
• Main Authors: Yi, Zhuwen, Shen, Tian, Cheng, Qia, Shuai, Lanjun, Wu, Xiaochuan
• Format: Article
• Language: English
• Subjects: Abatacept; Abatacept - pharmacology; Albumin; Animals; Anthracyclines; Automation; Belatacept; Biomedical research; CD80 antigen; Cholesterol; Corticosteroids; Creatinine; CTLA-4 protein; Disease; Doxorubicin - adverse effects; Doxorubicin - pharmacology; Electron microscopy; Enzyme-linked immunosorbent assay; Enzymes; Flow cytometry; Immunofluorescence; Immunoglobulins; Interleukin 17; Interleukin-17 - immunology; Kidney diseases; Kidney Diseases - chemically induced; Kidney Diseases - drug therapy; Kidney Diseases - immunology; Kidney Diseases - pathology; Kidneys; Laboratory animals; Life sciences; Lymphocytes; Lymphocytes T; Male; Microscopy; Nephropathy; Nephrotic syndrome; Normalizing; Pathogenesis; Prednisone; Proteins; Proteinuria; Proteinuria - chemically induced; Proteinuria - drug therapy; Proteinuria - immunology; Proteinuria - pathology; Rats; Rats, Sprague-Dawley; Serum albumin; Staining; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - pathology; Urea; Urine; Variance analysis
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2020/2347827

Objective. This study is aimed at investigating the efficacy of CTLA4-Ig abatacept in normalizing proteinuria and its possible mechanism in adriamycin-induced nephropathy (AIN) rats. Methods. A total of 32 healthy male Sprague-Dawley rats were randomly divided into a normal group, an AIN group, an abatacept group, and a prednisone group. Adriamycin (6.5 mg/kg) was injected once via the tail vein of rats to induce nephrotic syndrome. After adriamycin treatment, the abatacept group rats were given abatacept (0.5 mg/kg) once by intraperitoneal injection on day 14. In addition, the prednisone group rats were given prednisone (12.5 mg/kg) daily consecutively by gavage from day 14 to day 21. Blood, urine, and kidney tissue specimens were collected when sacrificed on day 21. The 24-hour urinary protein, serum albumin, cholesterol, creatinine, and urea nitrogen were then detected. An enzyme-linked immunosorbent assay was used to determine the level of urine CD80 and serum IL-17. Flow cytometry was used to investigate the prevalence of circulating Treg. Hematoxylin-eosin staining and electron microscopy were used for a renal histological study. Immunofluorescence staining was performed to confirm the CD80 expression of renal tissue. Results. The 24-hour urinary protein of the abatacept group was significantly lower than that of the prednisone group and the AIN group. The level of urine CD80 of the abatacept group was significantly lower than that of the AIN group. Compared with the AIN group and the prednisone group, the circulating Treg prevalence of the abatacept group was significantly higher, while the level of serum IL-17 was lower. A negative kidney staining of CD80 expression was demonstrated in each group in this study. The 24-hour urinary protein had a negative correlation with the circulating Treg prevalence and Treg/IL-17 and a positive correlation with the urine CD80 and serum IL-17. Urinary CD80 had a positive correlation with serum IL-17 and no correlation with the circulating Treg prevalence. Conclusions. CTLA4-Ig abatacept can reduce proteinuria of adriamycin-induced nephropathy rats, possibly at least partially as a result of regulating circulating Treg/IL-17. CTLA4-Ig abatacept could be a promising regimen for idiopathic nephrotic syndrome.